-->

Tag: sotorasib

Home / Established Year

, , ,

Sotorasib receives accelerated approval from the FDA for KRAS G12C mutant NSCLC

August 2021: The FDA granted accelerated approval to sotorasib (LumakrasTM, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) w..

, , , ,

The FDA has approved the first targeted therapy for a lung cancer mutation that was previously thought to be drug-resistant

August 20, 2021: Recently in May, 2021 Lumakras (sotorasib) was approved by the US Food and Drug Administration as the first treatment for adult patients with non-small cell lung cancer who have undergone at least one prior system..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy